June 21, 2023 6:55 AM EDTeight loss drugs have become the hottest selling drugs in the U.S. market this year, thanks in large part to Novo Nordisk’s products:and Rybelsus, approved in 2018 and 2019 to treat type 2 diabetes, and Wegovy, which was approved in 2021 to treat obesity.
is a tablet-based treatment [like metformin] because most physicians and patients find them easier. We were never strong in the tablet-based space; we did research but nothing really materialized in the clinic.had this glucose-lowering effect. We took that into research and worked on refining the mechanism, which led to the first launch of a daily injectable product from Novo Nordisk, in 2010.
At the time I took over it was actually a very difficult time for Novo Nordisk because we had seen price pressure on insulins. In 2016, we had to issue a significant downgrade in our expected growth and we saw our share price go down by some 40% because of price competition in insulins.our main competitor Eli Lilly
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TIME - 🏆 93. / 53 Read more »
Source: BBCNews - 🏆 3. / 97 Read more »